---
title: "Weight loss drug concept stocks performed strongly, with Hims rising 10.3%, BIIB up 4.98%, VTRX up 4"
description: "Weight loss drug concept stocks performed strongly, with Hims rising 10.3%, BIIB up 4.98%, VTRX up 4.44%, Viking Therapeutics up 3.34%, Vertex Pharma up 2.87%, Amgen up 2.48%, and Pfizer up 2.31%. In "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/239867061.md"
published_at: "2025-05-12T14:19:56.000Z"
---

# Weight loss drug concept stocks performed strongly, with Hims rising 10.3%, BIIB up 4.98%, VTRX up 4

> Weight loss drug concept stocks performed strongly, with Hims rising 10.3%, BIIB up 4.98%, VTRX up 4.44%, Viking Therapeutics up 3.34%, Vertex Pharma up 2.87%, Amgen up 2.48%, and Pfizer up 2.31%. In comparison, Eli Lilly saw a slight decline, Roche ADR fell 0.47%, and Novo Nordisk ADR dropped 0.91%

Weight loss drug concept stocks: Hims rose 10.3%, BIIB rose 4.98%, VTRX rose 4.44%, Viking Therapeutics rose 3.34%, Vertex Pharma rose 2.87%, Amgen rose 2.48%, Pfizer rose 2.31%, Eli Lilly slightly declined, Roche ADR fell 0.47%, Novo Nordisk ADR fell 0.91%

### Related Stocks

- [VKTX.US - Viking Therap](https://longbridge.com/en/quote/VKTX.US.md)
- [VRTX.US - Vertex Pharma](https://longbridge.com/en/quote/VRTX.US.md)
- [PFE.US - Pfizer](https://longbridge.com/en/quote/PFE.US.md)
- [LLY.US - Eli Lilly](https://longbridge.com/en/quote/LLY.US.md)
- [RHHBY.US - Roche](https://longbridge.com/en/quote/RHHBY.US.md)
- [AMGN.US - Amgen](https://longbridge.com/en/quote/AMGN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 15 年前投資 1000 美元在福泰製藥的今天價值多少 | Vertex Pharmaceuticals（納斯達克代碼：VRTX）在過去 15 年中實現了平均年回報率 17.22%，超出市場 5.55%。15 年前投資 1000 美元於 VRTX 股票，現在的價值為 10,742.55 美元，反映了 | [Link](https://longbridge.com/en/news/276269422.md) |
| 福泰製藥｜8-K：2025 財年 Q4 營收 31.9 億美元超過預期 |  | [Link](https://longbridge.com/en/news/275807197.md) |
| OS Therapies 為複發性、已完全切除的肺轉移性骨肉瘤中的 OST-HER2 提供全球監管更新 \| OSTX 股票新聞 | OS Therapies Inc.（紐約證券交易所代碼：OSTX）已提供其免疫療法 OST-HER2 的全球監管更新，該療法旨在預防複發性肺轉移性骨肉瘤。該公司計劃在 2026 年第一季度之前提交額外的生物標誌物數據，並完成在英國和歐洲的市 | [Link](https://longbridge.com/en/news/276114753.md) |
| Canbridge Pharmaceuticals Inc 將發行總計 8400 萬股認購股份 | Canbridge Pharmaceuticals Inc 將發行總計 8400 萬股認購股份 | [Link](https://longbridge.com/en/news/276022079.md) |
| Sionna Therapeutics 在古根海姆峯會上規劃了 2026 年中期的囊性纖維化催化劑，並重點介紹了 NBD1 穩定劑 | Sionna Therapeutics 在 2026 年古根海姆新興前景生物技術峯會上展示了其開發下一代囊性纖維化療法的戰略，重點關注 NBD1 穩定性。首席執行官 Mike Cloonan 強調了 NBD1 作為靶點的重要性，特別是對於影 | [Link](https://longbridge.com/en/news/276001201.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
